Idiopathic Intracranial Hypertension

Authored by , Reviewed by Dr Colin Tidy | Last edited | Meets Patient’s editorial guidelines

This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Idiopathic Intracranial Hypertension article more useful, or one of our other health articles.


Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Synonyms: pseudotumour cerebri, benign intracranial hypertension

Raised intracranial pressure in the absence of a mass lesion or of hydrocephalus. It is often idiopathic. Idiopathic intracranial hypertension (IIH) appears to be due to impaired cerebrospinal fluid (CSF) absorption from the subarachnoid space across the arachnoid villi into the dural sinuses.

Idiopathic intracranial hypertension can lead to significant visual impairment, so prompt recognition and treatment are needed to prevent potentially permanent visual changes including partial or total loss of vision.

  • Idiopathic intracranial hypertension most frequently occurs in obese women of childbearing age.
  • Its prevalence ranges between 0.5 and 2 per 100,000 of the general population and is expected to increase further as obesity increases worldwide[1] .
  • The incidence in the UK general population is approximately 4.7 per 100,000 and this has recently increased in parallel with obesity[2] .

Risk factors

  • Being overweight (90% patients).
  • There is an increased risk in women with menstrual irregularity.
  • Female-to-male ratio is between 3:1 to 8:1.
  • In women it may coincide with recent weight gain, fluid retention, the first trimester of pregnancy and the postpartum period.
  • It is increasingly prevalent in deprived populations[3] .

The underlying cause of the disease remains unknown. Several mechanisms have been proposed as the underlying cause of IIH:

  • An overproduction of cerebrospinal fluid (CSF).
  • Outflow obstruction.
  • Elevated pressure in the venous sinuses.
  • Dysfunction in the glymphatic pathway.
  • Hormonal alterations.

None adequately explains the whole clinical picture. Increasing evidence suggests that a CSF overproduction is unlikely to be the cause of IIH[1] .

Known associations include:

  • Headache tends to be the first symptom: generalised throbbing is worst first thing in the morning and last thing at night. It is relieved on standing (consistent with raised intracranial pressure). It is also aggravated by straining, coughing or a change in position. In many cases, the headache may be mild, nonspecific and have been present for many weeks or months.
  • Gradual visual field defects; moderate or gross bilateral papilloedema without significant focal intracranial signs. Identification of papilloedema is a common source of error in the diagnosis, as it is both under- and over-diagnosed[2] .
  • Daily transient visual obscurations (TVOs) ('greying out') on bending or stooping, halo or a short episode of visual Catherine wheel flashes, persistent blurring, scotoma or horizontal diplopia often occur.
  • Nausea, vomiting, drowsiness.
  • Diplopia (due to VI cranial nerve palsy, cognitive deficits, tinnitus and olfactory dysfunction are less common[1] .
  • Other causes of headache, including cerebral tumours and malignant hypertension.
  • Other causes of papilloedema.
  • Other causes of visual disturbance.

These are primarily to exclude any other possible cause of raised intracranial pressure.

  • Recommended blood tests include: FBC, ESR, iron studies, antinuclear antibodies, coagulation studies[5] .
  • Screening for Lyme disease is recommended in patients who have a history of exposure to Lyme disease in areas of endemic disease[6] .
  • CT or MRI scanning: the ventricles, in contrast to hydrocephalus, are normal or reduced in size.
  • Visual field charting: enlarged blind spot and peripheral field construction.
  • Lumbar puncture, if not contra-indicated by clinical features and pressure measurement. Monitor intracranial pressure if in doubt as to the diagnosis. Lumbar puncture reveals pressure greater than 250 mm CSF with normal constituents[2] .

The main principles of treatment are:

a) Treatment of the underlying disease.

b) Protection of the vision; and

c) Minimising morbidity caused by headache.

Treatment of the underlying disease

  • Weight reduction is the mainstay of this principle.. Patients with a BMI >30 kg/m2 should be sensitively counselled about weight management.
  • Amount of weight loss required is not known, but up to 15% weight was required to put IIH into remission in one cohort[7] .
  • Acetazolamide appears to be the most effective agent for lowering intracranial pressure although the 2015 Cochrane review shows only modest benefit for its use[8, 9] .
  • Topiramate is becoming popular as a therapeutic option because it treats migraine, suppresses the appetite and inhibits carbonic anhydrase.

Protection of the vision

  • Use of acetazolamide or topiramate reduces pressure on the optic nerve.

Headache morbidity

  • Headaches are usually migrainous.
  • Migraine preventers (that do not increase appetite) are appropriate.
  • Overuse of acute analgesic medication should be assessed, as this is a common observation in IIH patients.

Surgery

Surgical intervention may be considered if other measures are ineffective or there is a rapid or progressive decline in visual function. Surgical options include[10] :

  • Optic nerve sheath fenestration (decompression).
  • CSF shunting (lumbo-peritoneal,ventriculo-peritoneal shunt, ventriculojugular and vetriculoatrial shunts).
  • Intracranial venous sinus stenting

The treatment offered often depends on the local expertise available and should always occur in conjunction with weight loss.

  • Idiopathic intracranial hypertension is not known to be associated with any specific effect on mortality.
  • In a retrospective analysis the prognosis was good in 64.7% of the patients and 35.3% of the patients clinically worsened.
  • Recurrence of symptoms was observed in 33% of the patients and four patients had severe permanent vision loss.
  • Demographic features, initial complaints, mean ICP, and pathological magnetic resonance imaging findings were not associated with the prognosis.
  • Delay in treatment and generalised constriction in the visual field were associated with the poor prognosis.

Further reading and references

  1. Raoof N, Hoffmann J; Diagnosis and treatment of idiopathic intracranial hypertension. Cephalalgia. 2021 Apr41(4):472-478. doi: 10.1177/0333102421997093. Epub 2021 Feb 25.

  2. Wakerley BR, Mollan SP, Sinclair AJ; Idiopathic intracranial hypertension: Update on diagnosis and management. Clin Med (Lond). 2020 Jul20(4):384-388. doi: 10.7861/clinmed.2020-0232.

  3. Morrish P; Idiopathic intracranial hypertension. Clin Med (Lond). 2020 Sep20(5):e138. doi: 10.7861/clinmed.Let.20.5.6.

  4. Mollan SP, Davies B, Silver NC, et al; Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018 Oct89(10):1088-1100. doi: 10.1136/jnnp-2017-317440. Epub 2018 Jun 14.

  5. Pollak L, Zohar E, Glovinsky Y, et al; The laboratory profile in idiopathic intracranial hypertension. Neurol Sci. 2015 Jul36(7):1189-95. doi: 10.1007/s10072-015-2071-y. Epub 2015 Jan 18.

  6. Ramgopal S, Obeid R, Zuccoli G, et al; Lyme disease-related intracranial hypertension in children: clinical and imaging findings. J Neurol. 2016 Jan 6.

  7. Sinclair AJ, Burdon MA, Nightingale PG, et al; Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ. 2010 Jul 7341:c2701. doi: 10.1136/bmj.c2701.

  8. Supuran CT; Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother. 201515(8):851-6. doi: 10.1586/14737175.2015.1066675. Epub 2015 Jul 7.

  9. Piper RJ, Kalyvas AV, Young AM, et al; Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev. 2015 Aug 78:CD003434. doi: 10.1002/14651858.CD003434.pub3.

  10. Mukherjee N, Bhatti MT; Update on the surgical management of idiopathic intracranial hypertension. Curr Neurol Neurosci Rep. 2014 Mar14(3):438. doi: 10.1007/s11910-014-0438-8.

  11. KesKin AO, Idiman F, Kaya D, et al; Idiopathic Intracranial Hypertension: Etiological factors, Clinical Features, and Prognosis. Noro Psikiyatr Ars. 2018 Jul 557(1):23-26. doi: 10.5152/npa.2017.12558. eCollection 2020 Mar.

newnav-downnewnav-up